CA2466334A1 - Procedes servant a inhiber la proliferation des astrocytes et des cellules tumorales astrocytiques et a augmenter la survie des neurones et mises en application - Google Patents
Procedes servant a inhiber la proliferation des astrocytes et des cellules tumorales astrocytiques et a augmenter la survie des neurones et mises en application Download PDFInfo
- Publication number
- CA2466334A1 CA2466334A1 CA002466334A CA2466334A CA2466334A1 CA 2466334 A1 CA2466334 A1 CA 2466334A1 CA 002466334 A CA002466334 A CA 002466334A CA 2466334 A CA2466334 A CA 2466334A CA 2466334 A1 CA2466334 A1 CA 2466334A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- protein
- derivative
- astrocytes
- astrocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
L'invention concerne des procédés servant à inhiber la prolifération des astrocytes et des cellules tumorales astrocytiques. Elle concerne, de plus, des procédés servant à traiter un état associé à un défaut de la prolifération des astrocytes chez un sujet, ainsi que des procédés servant à traiter un état associé à la prolifération des cellules tumorales astrocytiques chez ce sujet. Elle concerne également des procédés servant à augmenter la survie des neurones. Elle concerne également des procédés servant à traiter la dégénérescence neuronale chez un sujet. Elle concerne également des compositions pharmaceutiques contenant la protéine NrS1 ou un acide nucléique et un véhicule acceptable sur le plan pharmaceutique. Elle concerne enfin une protéine NrS1 purifiée, un agent se liant à cette protéine NrS1, une trousse contenant un agent se liant à la protéine NrS1 et une composition contenant cette protéine NrS1 et un véhicule.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34471201P | 2001-11-07 | 2001-11-07 | |
US60/344,712 | 2001-11-07 | ||
PCT/US2002/035588 WO2003040333A2 (fr) | 2001-11-07 | 2002-11-07 | Procedes servant a inhiber la proliferation des astrocytes et des cellules tumorales astrocytiques et a augmenter la survie des neurones et mises en application |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2466334A1 true CA2466334A1 (fr) | 2003-05-15 |
Family
ID=23351677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002466334A Abandoned CA2466334A1 (fr) | 2001-11-07 | 2002-11-07 | Procedes servant a inhiber la proliferation des astrocytes et des cellules tumorales astrocytiques et a augmenter la survie des neurones et mises en application |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1578915A4 (fr) |
JP (1) | JP4503287B2 (fr) |
AU (1) | AU2002363524B2 (fr) |
CA (1) | CA2466334A1 (fr) |
NZ (1) | NZ532989A (fr) |
WO (1) | WO2003040333A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070042433A1 (en) * | 2003-03-26 | 2007-02-22 | Jianxin Bao | Neuregulin protein regulation of synaptic proteins |
EP1570857A1 (fr) * | 2004-02-27 | 2005-09-07 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Procédé pour inhiber la migration transépithéliale de leucocytes ou de cellules tumorales par un agent liant le CD81 et ses utilisations |
JP6861349B2 (ja) * | 2015-09-15 | 2021-04-21 | 中西 徹 | Cd81 lel特異的モノクローナル抗体 |
-
2002
- 2002-11-07 NZ NZ532989A patent/NZ532989A/en not_active IP Right Cessation
- 2002-11-07 AU AU2002363524A patent/AU2002363524B2/en not_active Ceased
- 2002-11-07 JP JP2003542580A patent/JP4503287B2/ja not_active Expired - Fee Related
- 2002-11-07 EP EP02802862A patent/EP1578915A4/fr not_active Ceased
- 2002-11-07 WO PCT/US2002/035588 patent/WO2003040333A2/fr active Search and Examination
- 2002-11-07 CA CA002466334A patent/CA2466334A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4503287B2 (ja) | 2010-07-14 |
WO2003040333A3 (fr) | 2006-04-27 |
EP1578915A4 (fr) | 2008-02-13 |
NZ532989A (en) | 2009-04-30 |
WO2003040333A2 (fr) | 2003-05-15 |
EP1578915A2 (fr) | 2005-09-28 |
AU2002363524B2 (en) | 2008-12-04 |
JP2005537779A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharp et al. | Differential cellular expression of isoforms of inositol 1, 4, 5‐triphosphate receptors in neurons and glia in brain | |
US6696303B2 (en) | Identifying substances using cells that express p75NTR | |
US8273855B2 (en) | Nogo, Caspr, F3 NB-3 useful in the treatment of injury and disease to the central nervous system | |
JP4986370B2 (ja) | Rgmおよびそのモジュレーターの用途 | |
Llorens et al. | Developmental analysis of Lingo‐1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l | |
CA2542171C (fr) | Modulateurs et modulation de l'interaction entre les rgm et la neogenine | |
CA2238007A1 (fr) | Clonage et expression du recepteur de .beta.app-c100 (c100-r) | |
JP4399260B2 (ja) | 神経再生ペプチドおよび脳損傷治療におけるその使用方法 | |
AU2002363524B2 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof | |
AU2002363524A1 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof | |
AU2002246766B2 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof | |
AU2002246766A1 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof | |
AU2007202818A1 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof | |
US20100129288A1 (en) | Gliomedin, Fragments Thereof and Methods of Using Same | |
KR20120030810A (ko) | 사이클로필린 b를 포함하는 아밀로이드원성 질환 예방 및 치료용 조성물 | |
CN117327168A (zh) | B2M-GluN1封闭肽、其药物组合物及用途 | |
Thomas-Crusells | Regulation of the neuronal chloride cotransporter KCC2 by neurotrophins | |
Bekirov | The role of classic cadherins in the development of hippocampal circuitry | |
Lee | P53-dependent and independent mechanisms by which the p53-related protein, ANp73, promotes neuronal survival | |
Carcea | Molecular mechanisms of cortical axon guidance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead | ||
FZDE | Dead |
Effective date: 20121107 |